About 27 million US adults used GLP-1 medications in 2025, according to CDC survey data released this week. Among those users, 44 percent modified how they took the drugs, skipping doses, delaying refills, or using smaller amounts than prescribed. More than half cited cost or availability as the reason.
Younger users faced steeper barriers. Fifty-eight percent of adults aged 14 to 39 who modified their use cited cost, compared with 20 percent of adults 65 or older.
At least 23 percent of GLP-1 users took compounded versions, which are made by compounding pharmacies to mimic FDA-approved drugs like Wegovy or Ozempic. An additional 9 percent did not know if their GLP-1 was compounded. The FDA does not review compounded drugs before sale. They generally have higher rates of preparation errors, contamination, and manufacturing problems than non-compounded drugs.
Among people using compounded GLP-1s, 62 percent took them in ways different from prescribed use. That compared to 36 percent of brand-name GLP-1 users.
The CDC researchers noted that nearly 40 percent of websites selling compounded GLP-1 medications stated or implied the drugs were FDA-approved. Nearly 80 percent used brand names in advertising, violating FDA regulatory standards. The researchers concluded that "understanding the safety and quality of compounded GLP-1 medications is an important public health consideration" and called for more research on dose and frequency adjustments people commonly make.